Education
About Us
Working with TipRanks
Follow Us
Petros Pharmaceuticals (PTPI)
OTHER OTC:PTPI
Total Valuation
Petros Pharmaceuticals has a market cap or net worth of $856.90K. The enterprise value is -$8.04M.
Market Cap$856.90K
Enterprise Value-$8.04M
Share Statistics
Petros Pharmaceuticals has 31,160,086 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,160,086
Owned by Insiders―
Owned by Institutions0.13%
Financial Efficiency
Petros Pharmaceuticals’s return on equity (ROE) is 1.92 and return on invested capital (ROIC) is 21749.66%.
Return on Equity (ROE)1.92
Return on Assets (ROA)-1.35
Return on Invested Capital (ROIC)21749.66%
Return on Capital Employed (ROCE)2.39
Revenue Per Employee284.00K
Profits Per Employee-795.49K
Employee Count18
Asset Turnover0.48
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio>-0.01
Price to Fair Value-10.59
Price to FCF-0.29
Price to Operating Cash Flow-0.01
PEG Ratio<0.01
Income Statement
In the last 12 months, Petros Pharmaceuticals had revenue of 5.11M and earned -14.32M in profits. Earnings per share was -0.02.
Revenue5.11M
Gross Profit3.90M
Operating Income-17.68M
Pretax Income-14.32M
Net Income-14.32M
EBITDA-10.81M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -2.96M and capital expenditures -24.59K, giving a free cash flow of -2.99M billion.
Operating Cash Flow-2.96M
Free Cash Flow-2.99M
Free Cash Flow per Share-0.10
Dividends & Yields
Petros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.92
52-Week Price Change-99.71%
50-Day Moving Average0.06
200-Day Moving Average4.42
Relative Strength Index (RSI)29.37
Average Volume (3m)562.43K
Important Dates
Petros Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Petros Pharmaceuticals as a current ratio of 0.40, with Debt / Equity ratio of 0.00%
Current Ratio0.40
Quick Ratio0.33
Debt to Market Cap0.09
Net Debt to EBITDA-0.34
Interest Coverage Ratio-31.52
Taxes
In the past 12 months, Petros Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Petros Pharmaceuticals EV to EBITDA ratio is -7.65, with an EV/FCF ratio of -31.49.
EV to Sales16.18
EV to EBITDA-7.65
EV to Free Cash Flow-31.49
EV to Operating Cash Flow-31.78
Balance Sheet
Petros Pharmaceuticals has $8.93M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$8.93M billion.
Cash & Marketable Securities$8.93M
Total Debt$0.00
Net Cash-$8.93M
Net Cash Per Share-$0.29
Tangible Book Value Per Share-$1.33
Margins
Gross margin is 76.34%, with operating margin of -345.84%, and net profit margin of -280.10%.
Gross Margin76.34%
Operating Margin-345.84%
Pretax Margin-280.10%
Net Profit Margin-280.10%
EBITDA Margin-211.54%
EBIT Margin-269.13%
Analyst Forecast
The average price target for Petros Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―